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S U M M A R Y
Background: Crimean-Congo hemorrhagic fever (CCHF) is a zoonotic viral disease with a high mortality
rate, and is one of the viral hemorrhagic fever syndromes. The average mortality rate of CCHF is 3–30%.
Research indicates that the longest incubation period after a tick bite is 12 days in CCHF disease.
However, in clinical practice, we encounter patients with CCHF as a result of tick bites with much longer
incubation periods (max. 53 days) than those reported in the literature. We present herein CCHF cases
presumably infected through tick bites and having incubation periods longer than the upper limit
reported in the literature.
Methods: We analyzed the cases of the 825 CCHF patients admitted to our hospital from 2007 to 2010
and found that 312 of them had undoubtedly been bitten by a tick. We searched the patient records for
information on the incubation period and found that 12 patients had experienced an incubation period of
over 12 days, which is the longest incubation period stated in the literature for patients deﬁnitely bitten
by a tick.
Results: A total of 12 patients (eight males and four females, with a mean age of 45 years) were recruited
into this study. Five (41.7%) of the 12 patients had positive CCHF virus-speciﬁc IgM antibodies, three (25%)
had a positive reverse transcription polymerase chain reaction test for CCHF virus, and four (33.3%) had
positive results in both tests during the acute and/or convalescent phase of the disease. In these cases, the
interval between tick bite and the onset of symptoms was a mean of 23.6 days (range 13–53 days).
Conclusion: Physicians serving in endemic regions should be aware of these longer incubation periods
after a tick bite. It is suggested that they perform more follow-ups on clinically and serologically highly
suspected patients than they currently do.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Crimean-Congo hemorrhagic fever (CCHF) is a zoonotic viral
disease that has a high mortality rate, and is one of the viral
hemorrhagic fever syndromes. The disease is caused by the CCHF
virus belonging to the genus Nairovirus in the Bunyaviridae family.
The average mortality rate of the disease is 3–30%.1 CCHF came to
the attention of modern medical science and was ﬁrst described as
a clinical entity in 1944–1945, and it remains an endemic disease
in different regions of Africa, Asia, and Eastern Europe.2
Sporadic cases or epidemics can be seen in human beings.3
Humans become infected by tick bites, crushing infected ticks,
contact with a CCHF patient during the acute phase of infection, or
by coming into contact with blood or tissues from viremic* Corresponding author. Tel.: +90 346 258 11 32.
E-mail address: dralikaya@gmail.com (A. Kaya).
1201-9712/$36.00 – see front matter  2011 International Society for Infectious Disea
doi:10.1016/j.ijid.2011.03.007livestock.1 Nosocomial transmission is a major mode of acquisition
of CCHF infection and accounts for a signiﬁcant portion of CCHF
cases and outbreaks worldwide.4 In general, the course of CCHF
infection has four distinct phases: incubation, pre-hemorrhagic,
hemorrhagic, and convalescence periods.1 After a short incubation
period, the CCHF reveals itself with generalized pain, myalgia,
fever, nausea, vomiting, abdominal pain, diarrhea, ecchymoses,
bleeding, and non-speciﬁc laboratory ﬁndings such as elevated
liver enzymes, thrombocytopenia, and leukopenia.1,5,6 The incu-
bation period after a tick bite is usually 3–7 days,7 but longer
incubation periods than usual – 9 and 12 days – have also been
reported.8,9 The incubation period may differ depending on several
factors, including viral dose and route of exposure.1 However, it is
difﬁcult to obtain precise data on the length of the incubation
period after a tick bite in CCHF disease.1,10,11
In clinical practice, we sometimes encounter patients with
CCHF following a tick bite who have had incubation periods much
longer than the longest periods reported in the literature. Whenses. Published by Elsevier Ltd. All rights reserved.
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to determine whether similar cases exist or not. However, we
found no studies conducted on CCHF patients presumably infected
by tick bite that investigated whether these longer incubation
periods existed or not. Hence the aim of this study was to report
CCHF cases presumably infected through tick bite with incubation
periods of longer than the upper limit reported in the literature.
2. Materials and methods
We analyzed the cases of the 825 CCHF patients admitted to our
hospital from 2007 to 2010. Three hundred and twelve of these
patients were undoubtedly bitten by a tick. We searched the
patient records for information regarding the incubation period
and found that 12 of the patients (3.8%) had experienced an
incubation period of over 12 days, which is the longest incubation
period reported in the literature among those patients undoubt-
edly bitten by a tick.
The study protocol was approved by the local human ethics
committee. Ten of 12 patients had been followed up by the
infectious diseases and clinical microbiology department, while
two patients had been followed up by the pediatrics department of
our center.
Tick bite was conﬁrmed when tick removal had been performed
by a doctor. Tick removal was documented following tick removal
performed by the patient him/herself. Charts of all hospitalized
CCHF patients were reviewed with respect to age, sex, history of
tick bite or history of removing a tick, other risk factors for CCHF
transmission, and interval between the tick bite and the onset of
symptoms. Outcomes and clinical and laboratory ﬁndings were
recorded for each patient. With the exception of tick bite, patients
with other risk factors for CCHF transmission were excluded from
the study. Patients who had removed the tick by themselves were
excluded, because the history of the patient or of their relatives
with regard to the timing of tick removal might have been
unreliable. Patients with a history of tick bite, those knowing theTable 1
Selected demographic, clinical and laboratory data of patients with Crimean-Congo he
Long incubation period (n = 1
Age, years, mean (range) 45 (15–77) 
Sex, n (%)
Female 4 (33.3) 
Male 8 (66.7) 
Incubation period (days), mean (range) 23.6 (13–53) 
Most common symptoms, n (%)
Myalgia 4 (33.3) 
Headache 4 (33.3) 
Fever 8 (66.7) 
Physical ﬁndings, n (%)
Fevera 4 (33.3) 
Conjunctival hyperemia 5 (41.7) 
Rash
Maculopapular 3 (25) 
Petechiae/ecchymosis 1 (8.3) 
Bleeding
Hematuria 2 (16.7) 
Hematemesis 1 (8.3) 
Selected laboratory tests, n (%)
Thrombocytopeniab 12 (100) 
Leukopeniac 7 (58.3) 
Elevated AST (IU/l) 10 (83.3) 
Elevated ALT (IU/l) 7 (58.3) 
Long aPTT (s) 4 (33.3) 
Death 0 (0) 
NS, not signiﬁcant; AST, aspartate aminotransferase; ALT, alanine aminotransferase; aP
a Axillary, 38 8C.
b Thrombocytopenia, platelet count <150  109/l.
c Leukopenia, leukocyte count <4  109/l.exact date of the tick bite, and those with clinical complaints
starting 13 days or more after the bite (by taking into consideration
the longest period reported in the literature) were included in the
study.
All serum specimens obtained for the deﬁnitive diagnosis of
CCHF were stored at 70 8C until testing. Acute and convalescent
phase serum samples were sent to the Virology Laboratory of Reﬁk
Saydam Hygiene Center in Ankara, Turkey for serological and
virological analyses. The deﬁnitive diagnosis of CCHF infection was
made based on typical clinical and epidemiological ﬁndings and
the detection of CCHF virus-speciﬁc IgM by ELISA or of genomic
segments of the CCHF virus by reverse transcription polymerase
chain reaction (RT-PCR), either in the acute and/or convalescent
phase of the disease.1,12 Since there was no case reported with
leptospirosis or hanta virus infection in our region, we did not rule
out these infections in our cases.
3. Results
A total of 12/312 patients (3.8%), including nine males and three
females, with a mean (range) age of 45 (15–77) years, were
recruited into this study. The mean incubation period in these
CCHF patients was 23.6 days (range 13–53 days).
Table 1 presents selected demographic, clinical, and laboratory
data of the patients with CCHF grouped according to the incubation
period (long incubation period n = 12; normal incubation period
n = 300). There were signiﬁcant differences between the study
groups with regard to the incubation period (days) and in the
percentages of patients with the most common symptom (fever),
leukopenia, elevated alanine aminotransferase (ALT), a long
activated partial thromboplastin time (aPTT), and death
(p < 0.05). The percentages of patients with myalgia, headache,
conjunctival hyperemia, rash, bleeding, thrombocytopenia, and
elevated aspartate aminotransferase (AST) were comparable
between those with a long incubation period and those with a
normal incubation period (p > 0.05).morrhagic fever grouped according to the length of the incubation period
2) Normal incubation period (n = 300) p-Value
45 (5–67) NS
112 (37.3) NS
188 (62.7) NS
5 (3–12) <0.05
94 (31.3) NS
98 (32.7) NS
272 (90.7) <0.05
225 (75) <0.05
123 (41) NS
91 (30.3) NS
30 (10) NS
59 (19.7) NS
22 (7.3) NS
289 (96.3) NS
251 (83.7) <0.05
275 (91.7) NS
247 (82.3) <0.05
195 (65) <0.05
20 (6.7) <0.05
TT, activated partial thromboplastin time.
Table 2
Selected demographic, clinical and laboratory data for the 12 patients with a long incubation period
Case
No.
Age (years)/
gender
Incubation
time (day)
Test time
(days)a
Recovery
time (days)b
CCHF- IgM CCHF
RT-PCR
PLT countc
( 109/l)
WBC countc
( 109/l)
ALT,c U/l AST,c
U/l
aPTT,c s
1 15/F 15 16 12  + 124 7.1 14 28 26
2 16/M 16 17 9  + 128 3.04 58 130 30
3 50/M 27 30 10  + 72 5.3 244 418 41
4 64/F 53 60 9 +  102 4.5 225 339 31
5 57/F 15 20 9 + + 39 2.5 167 331 44
6 71/M 23 30 10 +  110 2.6 51 81 32
7 20/M 13 14 7 + + 65 3.0 81 157 48
8 17/M 22 25 7 + + 91 1.7 26 101 43
9 43/M 41 45 11 +  89 2.1 46 95 47
10 47/M 24 28 19 + + 7 5.6 1451 2680 68
11 67/M 14 17 11 +  57 1.6 53 115 40
12 77/M 20 20 11 +  21 1.9 81 256 34
CCHF, Crimean-Congo hemorrhagic fever; RT-PCR, reverse transcription polymerase chain reaction; PLT, platelet; WBC, white blood cell; ALT, alanine aminotransferase; AST,
aspartate aminotransferase; aPTT, activated partial thromboplastin time; F, female; M, male.
a Time between the beginning of symptoms and collection of serum samples for ELISA and PCR.
b Time after the onset of symptoms.
c At admission.
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period was signiﬁcantly longer than that of the patients with a
normal incubation period (mean 23.6 (range 13–53) and mean 5
(range 3–12) days, respectively) (p < 0.05). Serological markers for
viral hepatitis A, B and C, human immunodeﬁciency virus,
cytomegalovirus, Toxoplasma, and Epstein–Barr virus were all
negative in all patients. Tube agglutination assays for Brucella spp
were also negative. In our patients, the most common symptom
was fever (66.7%), while the most common laboratory ﬁnding was
thrombocytopenia (100%).
Table 2 presents some of the demographic, clinical, and
laboratory data of these 12 patients. The interval between the
onset of symptoms and tick bite was 13, 14, 15, 15, 16, 20, 22, 23,
24, 27, 41, and 53 days, respectively. Five (41.7%) of the 12 patients
had positive CCHF virus-speciﬁc IgM antibodies, three (25%) had a
positive RT-PCR test for CCHF virus, and four (33.3%) were positive
in both tests during the acute and/or convalescent phase of the
disease. Five patients were bitten on the hips, while the other seven
patients were bitten on the right hand (n = 2), right armpit, right
ankle (n = 2), left arm, and left inguinal region. None of these
patients died during follow-up.
4. Discussion
Patients infected with CCHF virus in Turkey were ﬁrst reported
from the provinces of Tokat, Amasya, and Sivas in 2002.13–15 Since
2002, CCHF has become endemic in our country and large
outbreaks have been seen in the service area of our training
hospital during the spring and summer seasons. To date, 3135
conﬁrmed CCHF cases have been reported in our country.16
The incubation period of CCHF disease depends on how the
disease has been acquired. The incubation period is usually 1–3
days (maximum 12 days) in infections following tick bites. If the
disease develops via blood or tissue contact, the incubation period
is 5–6 days (maximum 13 days).6,17,18 In our cases, the incubation
periods after tick bite were evidently much longer than those
reported in the literature.
The longer incubation periods seen in our patients may have
occurred for a variety of reasons. Firstly, these patients might have
been infected by a different strain that has a longer incubation
period. Elevli et al.19 have recently reported a new CCHF virus
strain in Turkey with a longer incubation period. However, we
could not perform phylogenetic studies. Secondly, the viral load
received during the tick bite might have been lower in these
patients; the clinical course of patients with higher viral loads is
worse. Viral load is a useful predictor of disease progression andoutcomes. A high viral load tends to indicate a fatal outcome.20,21
The good survival rate for those patients with longer incubation
periods may suggest that these patients had a lower viral load.22,23
In addition, these patients had better laboratory results, including
white blood cell counts, ALT, and aPTT, compared to patients with
normal incubation periods.
During the summer, hundreds of people are admitted to the
local hospitals due to tick bites. In general, physicians follow up
their patients for a maximum of 10 days, because it is a presumed
fact that the incubation period after a tick bite is usually 1–3 days,
but a maximum of 12 days.6,9,17,18 As we have reported, although
infrequent (approximately 4%), the incubation period may be
longer than usual – up to 53 days.
In conclusion, physicians serving in endemic regions should be
aware of these longer incubation periods following tick bites, and
should follow-up the clinically and serologically highly suspected
patients for longer than they currently do.
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